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BACKGROUND. No existing animal model fully recapitulates all features of human pros-
tate cancer. The dog is the only large mammal, besides humans, that commonly develops
spontaneous prostate cancer. Canine prostate cancer features many similarities with its hu-
man counterpart. We sought to develop a canine model of prostate cancer that would more
fully represent the features of human prostate cancer than existing models.
METHODS. The Ace-1 canine prostate cancer cell line was injected transabdominally under
transrectal ultrasound (TRUS) guidance into the prostates of immunosuppressed, intact,
adult male dogs. Tumor progression was monitored by TRUS imaging. Some dogs were sub-
jected to positron emission tomography (PET) for tumor detection. Time of euthanasia was
determined based on tumor size, impingement on urethra, and general well-being. Euthana-
sia was followed by necropsy and histopathology.
RESULTS. Ace-1 tumor cells grew robustly in every dog injected. Tumors grew in subcapsu-
lar and parenchymal regions of the prostate. Tumor tissue could be identified using PET.
Histological findings were similar to those observed in human prostate cancer. Metastases to
lungs and lymph nodes were detected, predominantly in dogs with intraprostatic tumors.
CONCLUSIONS. We have established a minimally invasive dog model of prostate cancer.
This model may be valuable for studying prostate cancer progression and distant metastasis.
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INTRODUCTION
Prostate cancer is the most frequently diagnosed
malignancy and the third leading cause of cancer-re-
lated death in men in developed countries [1]. Animal
models of prostate cancer, including a wide variety of
transgenic, knockout, and xenograft mouse models,
have proven extremely valuable in expanding our
knowledge of this disease [2]. However, prostate can-
cer is a complex, multifactorial disease process, and
despite the advances provided by animal models, no
existing animal model fully recapitulates all features
of human prostate cancer [3]. Besides humans, the
dog is the only other large mammal which commonly
develops spontaneous prostate cancer [4]. Similar to
humans, dogs develop benign prostatic hyperplasia
(BPH) [5], high-grade prostatic intraepithelial neopla-
sia, and invasive prostate cancer spontaneously with
age [4,6]. The dog prostate also shares a variety of
anatomic and functional similarities with humans [4].
In addition, the disease process in dogs with sponta-
neous prostate cancer is very similar to that of
humans, including a tendency to metastasize to bone,
a feature which mouse models of induced prostate
cancer do not share [7]. We sought to develop a dog
model of prostate cancer that would more fully repre-
sent the features of human prostate cancer than
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existing rodent models. Such a dog model could
prove invaluable in pre-clinical studies of diagnostic
and therapeutic regimens for both human and canine
prostate cancer.
MATERIALSANDMETHODS
CellCulture
The Ace-1 cell line is a spontaneously immortalized
canine prostate cancer cell line derived from a sponta-
neous prostatic adenocarcinoma that forms osteoblas-
tic bone metastases in nude mice after intracardiac
injection [8–10]. Cells were maintained at 378C and 5%
CO2 in RPMI medium supplemented with 10% fetal
bovine serum (FBS) and 1% penicillin/streptomycin.
Subjects
After receiving approval from the university com-
mittee for animal use and care, 12 intact 5- to 6-year-
old male beagles weighing 11–14 kg were obtained.
Subjects were administered oral cyclosporine at a
starting dose of 200 mg daily (range of 14.6–17.4 mg/
kg). Cyclosporine levels were monitored biweekly
and cyclosporine administration was titrated to
achieve therapeutic cyclosporine trough levels be-
tween 400 and 600 ng/dl. Once this window was
achieved subjects were maintained in the therapeutic
window throughout the remainder of the study.
Tumor Implantation
Once serum cyclosporine concentrations were main-
tained in the therapeutic window for 1 week, dogs
were anesthetized with subcutaneous acepromazine
(0.1 mg/kg) and intravenous propofol (2–8 mg/kg)
and the trachea was intubated. The dogs were prepped
with a tap water enema with digital rectal disimpac-
tion after intubation. Inhalational anesthesia (isoflurane
1–2%) was maintained throughout the procedure. All
subjects received intramuscular Penicillin G benza-
thine/procaine (40,000 IU/kg) prior to the procedure
for prophylaxis. The lower abdomen was shaved be-
fore positioning each subject supine on the procedural
table and the lower abdomen was then prepped with
povidine iodine and draped in a sterile fashion. Trans-
rectal ultrasound (TRUS) imaging was performed
using a Logiq 6 ultrasound scanner (GE Healthcare,
Waukesha, WI) with a model ERB probe positioned
manually. The prostate volume was estimated using
the ellipsoid estimation (H  W  L  p/6). A 22-
gauge spinal needle was introduced through the ab-
dominal skin to the left of the penis and passed into
the left lobe of the prostate obliquely (in order to
lengthen the needle path) under TRUS guidance. Both
sagittal and transverse plane imaging was used to veri-
fy placement of the needle into the central left lobe at
least 1 cm from the urethra. Once in position, a cellular
suspension of Ace-1 cells was injected into the prostate.
In the first two subjects, 0.5 cc of a 1.2  108 cells/cc
suspension was injected into the left hemiprostate
(6  107 cells) at a single site. Subsequent subjects had
0.5 cc of a 6  107 cells/cc suspension of Ace-1 cells
(3  107 cells) in medium injected into the prostate in
0.1 cc increments (5 boluses total) with slight reposi-
tioning of the needle between boluses in an effort to
improve central tumor uptake. In all subjects, injection
of cells was associated with the appearance of hyper-
echoic foci in the prostatic parenchyma (Fig. 1). If the
initial injection resulted in clear efflux of suspension
into the urethra, the needle was repositioned more lat-
erally prior to the next injection. For subjects 6–12, the
last aliquot of cells was followed with 0.2 cc of 0.1%
gelatin in saline to help create a ‘‘plug’’ in the prostatic
capsule.
TumorSurveillance
Following injection of tumor cells, subjects were
monitored for signs of disseminated tumor with daily
physical examination. All subjects underwent weekly
TRUS under anesthesia, using the same anesthetic pro-
tocol as above, to examine tumor growth and changes
in prostate volume using the ellipsoid method. Begin-
ning 2 weeks post-injection weekly flexible cystoureth-
roscopy with an 8.2 French flexible ureteroscope
(Dur-8, Gyrus ACMI) was performed following TRUS
under anesthesia to assess for intraurethral tumors.
CirculatingTumorCells (CTCs)
The Circulating Tumor Cell (CTC) Assay (Veridex,
LLC, Raritan, NJ) was performed on whole blood
Fig. 1. Orthotopic injection of Ace-1 tumor cells into dog pros-
tate under transrectal ultrasound guidance.Note the hyperechoic
appearanceofinjectionsite (arrowhead) inlefthemiprostate.
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samples collected from four dogs prior to euthanasia.
This assay uses a ferrofluid-based capture reagent
and immunofluorescent reagent to identify circulat-
ing tumor cells (CTCs). The ferrofluid reagent con-
tains magnetic particles and antibodies that target the
EpCAM antigen and immunomagnetically captures
those cells which express EpCAM from other compo-
nents within the blood sample. The fluorescent re-
agent which stains the captured cells includes anti-
CK-Phycoerythrin (PE, antibodies to cytokeratins 8,
18, and 19), DAPI and anti-CD45-Allophycocyanin
(APC). Cell images are evaluated for shape, size, and
staining pattern. The CTC Assay is reported out as
the number of CTCs found in a 7.5 ml sample of
whole blood.
PositronEmissionTomography (PET)
andDataAnalysis
PET scan imaging was performed on two dogs.
Following overnight fasting, both subjects were anes-
thetized with IV acepromazine/propofol followed by
endotracheal intubation and maintenance on 1–3%
isoflurane as described previously. Anesthetized ani-
mals were positioned supine in a microPET P4 scan-
ner (Concorde Microsystems, Inc., Knoxville, TN)
centering the prostate in the field of view. The scan-
ner table was extended to support the length of the
dogs. Following a measured transmission scan, the
first dog received a 60-min dynamic PET study of the
pelvis immediately after intravenous injection of
4.1 mCi of 11C-choline. The second dog received a 60-
min pelvic scan after injection of 6.2 mCi of 11C-me-
thionine. Data were reconstructed using iterative or-
dered subset expectation maximization-maximum a
posteriori (OSEM-MAP) yielding a reconstructed im-
age resolution of approximately 1.4 mm. Immediately
after imaging, both animals were euthanized and
specimens collected and processed as described else-
where following complete decay for radioactivity.
Euthanasia andSpecimenProcessing
Subjects were euthanized with pentobarbital sodi-
um 140–160 mg/kg IV 2–6 weeks after Ace-1 cell in-
jection. Time of euthanasia was determined based on
tumor size, impingement on urethra, and general
subject well-being. At the time of euthanasia TRUS
imaging was performed, followed by a suprapubic in-
cision entering the peritoneum. The prostate and
bladder were then surgically removed en bloc along
with any extraprostatic tumor. A bilateral pelvic
lymph node dissection was then conducted including
the obturator and internal, external, and common iliac
lymph nodes. If further retroperitoneal lymph nodes
were enlarged they were harvested. Next, the adrenal
glands and a portion of the liver were harvested fol-
lowed by a thoracotomy and bilateral pneumonecto-
my with excision of any macroscopic or palpable
lung nodules. Harvested tissues were fixed in forma-
lin for 1 week, cut into 5-mm thick slabs, dehydrated
in 25% ethanol, paraffin embedded, cut using a mi-
crotome in 5 mm sections at 1 mm increments,
mounted, and stained with hematoxylin and eosin for
histologic assessment. All specimens were reviewed
and interpreted by a veterinary pathologist (TJR).
RESULTS
Our initial procedure was to immunosuppress the
dogs prior to tumor implantation to minimize rejec-
tion of the implanted cells by the host dogs. Cyclo-
sporine is a commonly used immunosuppressant for
tissue implantation; however, there is a wide variation
in pharmacokinetics among individuals which
requires close monitoring of cyclosporine levels to
achieve appropriate immunosuppressive serum levels.
We found that the final dose of cyclosporine needed
to maintain target trough levels of 400–600 ng/dl var-
ied widely among individuals and ranged from 12.1
to 40.0 mg/kg/day (Fig. 2). Stable cyclosporine target
levels were achieved in approximately 2 weeks in
most dogs.
Ace-1 tumor cells grew robustly in every dog
injected. Following injection of cells, a hyperechoic area
could be identified at the injection site on transrectal
ultrasound images (Fig. 1). Injection of the first two
dogs, which was performed as a single bolus, resulted
in tumor establishment within 1 week in the subcapsu-
lar area of the prostate (Fig. 3). Tumors arising within
Fig. 2. Cyclosporine (CsA)dosages (n ¼ 12).Eachdoginitiallyre-
ceived 200 mgCsAdaily, resulting in a starting dose range of14.6^
17.4 mg/kg.Once stablebloodlevelswerereached, finaldosesneed-
ed to maintain blood levels at 400^600 ng/dl ranged from12.1 to
40.0 mg/kgdaily.
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and extending from the prostatic capsule displayed
clear delineation between the tumor and periprostatic
fat sonographically (Fig. 3A). These capsular tumors
were likely due to leakage of Ace-1 cells from primary
injection sites and formed tumors with thick capsules
of granulation tissue. These tumors continued to grow
rapidly until the dogs were euthanized at 4 weeks
post-tumor cell injection. In some instances, injection of
tumor cells was followed by injection with agarose in
an attempt to ‘‘plug’’ the injection sites and retain tu-
mor cells within the prostate. The addition of agarose
did not appear to have any impact on tumor location
(data not shown).
To encourage tumor growth within the prostate pa-
renchyma rather than in the subcapsular area, we re-
fined our injection technique for the remaining 10
dogs by dividing the same volume of tumor cell sus-
pension between five separate incremental injections
as outlined above. In addition, we also reduced the
cell number injected by half to slow tumor develop-
ment to a moderate rate to facilitate tumor monitor-
ing. Subsequent to modification of the injection
technique, 60% of the dogs injected developed Ace-1
tumors within the prostate parenchyma, while the
other 40% developed tumors within the subcapsular
area of the prostate. On transrectal ultrasound, intra-
prostatic tumors appeared as discrete hypoechoic
lesions within the adjacent normal appearing paren-
chyma (Fig. 4A). In some dogs, prostate volume in-
creased over time (Fig. 4B); however, this was not
readily apparent in all dogs.
Histopathological analysis revealed moderate cystic
or papillary benign prostatic hyperplasia in all dogs.
Most dogs had mild to moderate lymphoplasmacytic
prostatitis. Tumors were limited to the lateral prostatic
lobe that received the injection of tumor cells. Tumors
that grew in the prostate parenchyma formed poorly
demarcated masses that invaded into the prostatic
glands, ducts, and interlobular septae (Fig. 5). Tumor
nodules often had central necrosis. The prostate carci-
nomas induced mild desmoplasia. In some cases,
there was invasion of Ace-1 cells into and around ves-
sels or nerves. Overall, the Ace-1 cells formed solid,
poorly differentiated carcinomas with epithelial to
mesenchymal cell transformation and an alveolar or
cribiform growth pattern. The prostate carcinoma cells
were large and polygonal with some cells mildly spin-
dle-shaped. The cytoplasm was darkly stained and
relatively basophilic. Nuclei were round to oval with
prominent central nucleoli and occasional mitoses. As
a small percentage of human prostate cancers demon-
strate neuroendocrine features, we had evaluated for
these properties in Ace-1 xenografts. We did not iden-
tify any neuroendocrine features in Ace-1 tumors and
they are Chromogranin A negative (data not shown).
Fig. 3. Appearance of subcapsular Ace-1 prostate cancer in
dogs. A: Transrectal ultrasound image of subcapsular tumor (T).
B: In situ subcapsular tumor (T).C: Formalin-fixed sections of sub-
capsular tumor (T).D: Histology of the entire prostate glandwith
subcapsular tumor (T) showing multinodular, invasive, prostate
carcinoma growing in prostate capsule and adjacent connective
tissue and skeletalmuscle.E: Magnified appearance of subcapsular
tumor showingdesmoplasia andmarkedcentralnecrosis.
Fig. 4. Progressive growth of Ace-1 tumors in dog prostate.
A: Transrectal ultrasound images in the same subject over time
demonstrating tumor growth. Tumor (T). Normal prostate (P).
B:Prostatevolumeover timein the samedog.
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Metastases to distant sites, including lungs and re-
gional lymph nodes, occurred in 50% of dogs follow-
ing technique refinement (Fig. 6 and Table I). The
majority of the metastases (80%) occurred in dogs
with intraprostatic tumors, while 20% (n ¼ 1) oc-
curred in a dog with a subcapsular tumor. Metastatic
tumors formed in regional lymph nodes, lungs, and
adjacent fascia. Metastases in the lungs formed nod-
ules adjacent to bronchioles and often had lympho-
plasmacytic inflammation (Fig. 6A). Metastases in
regional lymph nodes formed discrete nodules in the
cortex often with central necrosis (Fig. 6B). Circulat-
ing Ace-1 tumor cells were not detected by CTC assay
(data not shown). We were able to confirm that the
assay was working properly by ‘‘spiking’’ some ca-
nine serum samples with human prostate cancer cells
(PC-3), which served as a positive control. Ace-1
tumor cells did establish metastases at distant sites,
indicating that these canine tumor cells were in circu-
lation, but not detectable by CTC assay using the
available human reagents.
In order to determine if the tumors could be im-
aged, we subjected two dogs to PET. Use of 11C-
choline allowed detection of subcapsular tumor in the
abdominal wall, but not the primary prostate tumor.
In contrast, use of 11C-methionine allowed for detec-
tion of both tumor tissue in the prostate and subcap-
sular tumor (Fig. 7).
DISCUSSION
A wide variety of animal models for prostate can-
cer exist [11,12]. The majority of those animal models
have been developed in rodents, especially mice, in-
cluding xenograft and genetically engineered mouse
models (GEMMs) [2]. None of the mouse models fully
recapitulate the features of prostate cancer as it occurs
in humans. While these models are well established,
readily available, and relatively economical, they rep-
resent induced rather than spontaneous disease, mak-
ing them less biologically relevant than a model such
as the dog in which prostate cancer develops sponta-
neously with age as it does in humans [4]. Dogs are
more genetically heterogeneous than most mouse
models which is representative of what occurs in the
human population. Intact male dogs are the only
Fig. 5. Appearance of intraprostatic Ace-1tumor in dog followingmodifications in injection technique.A:Transrectal ultrasound image
of intraprostatic tumor (T).B:Gross appearance ofprostate containingintraprostatic tumor.C:Formalin-fixed sections of intraprostatic tu-
mor (T).D:Histologyof the entireprostate glandwith an intraprostatic tumor (T).Prostate carcinoma invaded into prostatic glands, ducts,
and interlobular septae.E: Histologic appearance of tumor showing central necrosis and desmoplasia.F: Lymphovascular invasion of Ace-1
prostate cancer cells.G: Upper panel (A) demonstrates two foci of Ace-1canine prostate cancer (arrows) growing adjacent to the urethra
(upper right).Normalglands are locatedin theupper left.The foci ofprostate cancer are in a region of chronic lymphoplasmacytic prostatitis.
Lowerpanel (B) showsahighermagnificationof theAce-1prostatecancercellsgrowingin solidpattern.
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large mammal besides humans that commonly and
spontaneously develop benign prostatic hyperplasia
(BPH) [13], high-grade prostatic intraepithelial neo-
plasia, and invasive prostate cancer with age [6,14].
This occurs independent of dog breed. There are rat
strains, such as Lobund–Wistar [15,16] and ACI/Seg
[7], which uncommonly develop spontaneous pros-
tate cancer, but the tumor phenotype is different and
metastases do not occur as seen in men with prostate
cancer [17]. In addition to the biologic relevance of
spontaneous disease in the dog, there is the advantage
of their larger body size compared to rodents, which
allows diagnostic and surgical procedures that are
used in human clinical practice. The dog prostate also
shares anatomic and functional similarities with
humans, including the presence of a circumferential
bi-lobed single gland (compared with 4 in mice and
rats) [18]. Dogs with prostate cancer develop distant
metastases, including bone, which shows mixed oste-
oblastic and osteolytic lesions with the formation of
Fig. 6. Gross andhistologic appearanceofmetastasesindogsinjectedorthotopicallywithAce-1prostate cancercells.A:Lungmetastases.
Panel1,Gross appearance of lungmetastases (M).Panel 2,Histologic appearance of lungmetastases.Panel 3,magnifiedhistologic appearance.
Themetastasismayhaveoriginatedinaperibronchiolar artery.Itis invasiveinto thepulmonaryparenchyma andis surroundedbyarimoflym-
phoplasmacytic inflammation. Panel 4, Lungmetastases growing in a peribronchial vessel with invasion into the pulmonary parenchyma. A
bronchiole is present in the upper left.The region hasmoderate lymphoplasmacytic inflammation. Alveoli are present on the right. Panel 5,
Higher magnification of Ace-1cells growing in solid and cribiform patterns.B: Lymph nodemetastases. Panel1,Gross appearance of lymph
nodemetastases.Panel 2,Histologic appearance oflymphnodemetastases.Panel 3,magnifiedappearance oflymphnodemetastases.Thereis
widespread,marked, cortical (T-cell) atrophy.This is a focalmetastatic carcinomawith epithelial tomesenchymalcell transformation, desmo-
plasia,multifocalnecrosis andapoptosis, andahighmitotic index.
TABLE I. Tumor Incidence andMetastasis in Dogs InjectedOrthotopicallyWithMultiple bolusesOf Ace-1Prostate Cancer
Cells
Tumor take Tumor in capsule Tumor in prostate Lung Mets LN Mets All Mets
10/10 4/10 6/10 4/10 4/10 5/10
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new woven bone, as seen in humans [7]. Rodents
rarely develop bone metastases, and when they do
they are typically osteolytic [17].
Similar to human prostate cancer cells, Ace-1 cells
express factors such as parathyroid hormone-related
protein (PTHrP), cathepsin K, keratins 8/18, and
vimentin [8]. PTHrP has been implicated in the devel-
opment of bone metastases of human prostate cancer
[19]. Cathepsin K has been suggested to play a role in
prostate cancer progression to bone in men [20]. Ex-
pression of keratins and vimentin in human cancers
may indicate that the cancer is undergoing epithelial
to mesenchymal transition (EMT) [21], a feature
which is observed in tumors derived from the Ace-1
cell line. Ace-1 cells are androgen receptor (AR) nega-
tive, as are most canine prostate cancers. This may
conflict with many human prostate cancers which can
have normal or increased AR expression although
heterogeneous AR expression is often reported [22].
Another difference among human and canine pros-
tate cancers is the observation that many canine pros-
tate cancers can form in castrated dogs [23]. In
contrast, prostate cancer forms in men with intact tes-
tes. Thus, these differences in prostate pathophysiolo-
gy should be considered upon using this model.
Despite the advantages of the dog model, as with
all animal models, there are some disadvantages.
Dogs are more expensive to maintain and large ani-
mal housing space must be available. It can also be
difficult to obtain older, intact male dogs necessary
for these studies, though dog suppliers may be able to
provide retired breeders. In addition, prostate cancer
in dogs is typically late-stage and androgen-indepen-
dent. In contrast, prostate cancer in men is initially
androgen-dependent and responsive to androgen ab-
lation therapy and later progresses to androgen inde-
pendence [4,24,25]. Despite these shortcomings, the
advantages of the dog as a model for prostate cancer
outweigh its potential disadvantages, especially in
being able to provide a large animal model of prostate
cancer. More specifically, canine prostate cancer is po-
tentially a good model of late stage, androgen-inde-
pendent prostate cancer with metastasis to bone,
lymph nodes, and lung.
A similar dog model for prostate cancer was re-
cently described [26]. This study was able to establish
orthotopic prostate cancer in dogs immunosup-
pressed with cyclosporine using the DPC-1 canine
cell line. Similar to our findings, tumors developed
readily in the prostate and metastasis to lung and
lymph nodes was detected. However, in that study,
they established tumors through an invasive laparoto-
my; whereas, we established tumors in a less-invasive
manner by using transabdominal percutaneous injec-
tion under ultrasound guidance. We also optimized
our cyclosporine dosages for each individual dog to
maintain consistent blood levels across subjects both
prior to and after tumor cell injection. Furthermore,
we were able to monitor tumors by transrectal ultra-
sound rather than transabdominal sonography, which
is more clinically relevant. We were also able to detect
both primary tumor and metastases via PET imaging.
Identifying precise tumor boundaries and distin-
guishing tumor from normal surrounding prostate
parenchyma can be challenging using any form of ul-
trasound, thus the use of PET imaging can more accu-
rately differentiate the two. Both studies ultimately
demonstrate the utility and feasibility of a dog model
for prostate cancer.
CONCLUSIONS
In conclusion, we have successfully established a
minimally invasive dog model of prostate cancer. Our
model consistently developed tumors following
orthotopic injection of syngeneic prostate cancer cells,
and modifications in our technique led to improve-
ments in localization of these tumors to the prostatic
parenchyma. Few to no side effects were observed
due to immunosuppression with cyclosporine,
though the rapidity with which these tumors devel-
oped leads us to question whether these tumors may
be able to grow either without or with decreased im-
munosuppression in future studies. We also observed
metastases in approximately half of our dogs, indicat-
ing the utility of this model for studying prostate can-
cer progression and distant metastasis.
The orthotopic Ace-1 dog model of prostate cancer
has great potential for advancing studies in this field.
Potential areas of investigation include chemothera-
py, surgical therapy, local ablative therapy, studies on
growth, local invasion, and metastasis, bone metasta-
sis studies on bone formation and resorption, and
investigations on tumor microenvironment in a host
that naturally develops this disease.
Fig. 7. Transaxial (A) and coronal (B) 11C-methionine PET images
of anuntreatedcontroldoginjectedwithAce-1prostate cancercells.
Images were taken prior to euthanasia at 6 weeks post-injection.
White arrows ¼ intraprostatic tumor.Yellow arrow ¼ extracapsu-
racapsular tumor.
958 Kelleret al.
The Prostate
REFERENCES
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D.
Global cancer statistics. CA Cancer J Clin 2011;61(2):69–90.
2. Wang F. Modeling human prostate cancer in genetically engi-
neered mice. Prog Mol Biol Transl Sci 2011;100:1–49.
3. Hensley PJ, Kyprianou N. Modeling prostate cancer in mice:
Limitations and opportunities. J Androl 2012;33(2):133–144.
4. Leroy BE, Northrup N. Prostate cancer in dogs: Comparative
and clinical aspects. Vet J 2009;180(2):149–162.
5. Coffey DS, Walsh PC. Clinical and experimental studies of be-
nign prostatic hyperplasia. Urol Clin North Am 1990;17(3):
461–475.
6. Waters DJ, Bostwick DG. The canine prostate is a spontaneous
model of intraepithelial neoplasia and prostate cancer progres-
sion. Anticancer Res 1997;17(3A):1467–1470.
7. Rosol TJ, Tannehill-Gregg SH, LeRoy BE, Mandl S, Contag CH.
Animal models of bone metastasis. Cancer 2003;97(3 Suppl):
748–757.
8. LeRoy BE, Thudi NK, Nadella MV, Toribio RE, Tannehill-
Gregg SH, van Bokhoven A, Davis D, Corn S, Rosol TJ. New
bone formation and osteolysis by a metastatic, highly invasive
canine prostate carcinoma xenograft. Prostate 2006;66(11):
1213–1222.
9. Thudi NK, Martin CK, Murahari S, Shu ST, Lanigan LG, Wer-
beck JL, Keller ET, McCauley LK, Pinzone JJ, Rosol TJ. Dick-
kopf-1 (DKK-1) stimulated prostate cancer growth and
metastasis and inhibited bone formation in osteoblastic bone
metastases. Prostate 2011;71(6):615–625.
10. Thudi NK, Martin CK, Nadella MV, Fernandez SA, Werbeck
JL, Pinzone JJ, Rosol TJ. Zoledronic acid decreased osteolysis
but not bone metastasis in a nude mouse model of canine pros-
tate cancer with mixed bone lesions. Prostate 2008;68(10):
1116–1125.
11. Pienta KJ, Abate-Shen C, Agus DB, Attar RM, Chung LW,
Greenberg NM, Hahn WC, Isaacs JT, Navone NM, Peehl DM,
Simons JW, Solit DB, Soule HR, VanDyke TA, Weber MJ, Wu
L, Vessella RL. The current state of preclinical prostate cancer
animal models. Prostate 2008;68(6):629–639.
12. Russell PJ, Voeks DJ. Animal models of prostate cancer. Meth-
ods Mol Med 2003;81:89–112.
13. Mahapokai W, Van Sluijs FJ, Schalken JA. Models for studying
benign prostatic hyperplasia. Prostate Cancer Prostatic Dis
2000;3(1):28–33.
14. Madewell BR, Gandour-Edwards R, DeVere White RW. Canine
prostatic intraepithelial neoplasia: Is the comparative model
relevant? Prostate 2004;58(3):314–317.
15. Pollard M, Suckow MA. Hormone-refractory prostate cancer in
the Lobund-Wistar rat. Exp Biol Med (Maywood) 2005;230(8):
520–526.
16. Pollard M. The Lobund-Wistar rat model of prostate cancer.
J Cell Biochem Suppl 1992;16H:84–88.
17. Blouin S, Basle MF, Chappard D. Rat models of bone metasta-
ses. Clin Exp Metastasis 2005;22(8):605–614.
18. Evans HE. Miller’s anatomy of the dog, 3rd edition. Philadel-
phia: W.B. Saunders; 1993.
19. Park SI, McCauley LK. Nuclear localization of parathyroid hor-
mone-related peptide confers resistance to anoikis in prostate
cancer cells. Endocr Relat Cancer 2012;19(3):243–254.
20. Podgorski I, Linebaugh BE, Sloane BF. Cathepsin K in the bone
microenvironment: Link between obesity and prostate cancer?
Biochem Soc Trans 2007;35(Pt 4):701–703.
21. Thompson EW, Newgreen DF, Tarin D. Carcinoma invasion
and metastasis: A role for epithelial-mesenchymal transition?
Cancer Res 2005;65(14):5991–5995; discussion 5995.
22. Avila DM, Zoppi S, McPhaul MJ. The androgen receptor (AR)
in syndromes of androgen insensitivity and in prostate cancer.
J Steroid BiochemMol Biol 2001;76(1–5):135–142.
23. Teske E, Naan EC, van Dijk EM, Van Garderen E, Schalken JA.
Canine prostate carcinoma: Epidemiological evidence of an
increased risk in castrated dogs. Mol Cell Endocrinol 2002;
197(1–2):251–255.
24. Argyle DJ. Prostate cancer in dogs and men: A unique oppor-
tunity to study the disease. Vet J 2009;180(2):137–138.
25. Fork MA, Murua Escobar H, Soller JT, Sterenczak KA, Willen-
brock S, Winkler S, Dorsch M, Reimann-Berg N, Hedrich HJ, Bul-
lerdiek J, Nolte I. Establishing an in vivo model of canine prostate
carcinoma using the new cell line CT1258. BMC Cancer 2008;8:240.
26. Anidjar M, Scarlata E, Cury FL, Rocha J, Hamel L, Luz M, Che-
valier S. Refining the orthotopic dog prostate cancer (DPC)-1
model to better bridge the gap between rodents and men. Pros-
tate 2012;72(7):752–761.
CanineModel forProstateCancer 959
The Prostate
